Neumora Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Neumora Therapeutics, Inc. (NMRA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-243.79-235.93-130.90-237.31-99.27
Depreciation & Amortization0.63-3.040.590.540.11
Stock Based Compensation39.9917.248.304.271.68
Change in Working Capital22.64-5.50-6.95-0.96-3.12
Change in Accounts Payable2.87-0.58-1.25-0.76-4.67
Change in Other Working Capital19.76-8.3215.33-0.201.55
Other Operating Activities3.3181.2215.331.043.99
Net Cash from Operating Activities-182.94-163.28-114.90-75.42-26.76
Investing Activities
Capital Expenditures0.000.12-0.51-0.82-1.30
Acquisitions-0.78-4.590.000.002.81
Purchases of Investments-69.7869.09-226.370.000.00
Sales/Maturities of Investments-0.7869.0971.870.000.00
Other Investing Activities0.000.000.000.00-12.75
Net Cash from Investing Activities-70.5664.39-168.01-0.82-11.24
Financing Activities
Common Stock Issued21.60233.382.663.473.19
Common Stock Repurchased0.00-0.490.000.000.00
Other Financing Activities7.91-0.49-0.74-1.21-0.90
Net Cash from Financing Activities21.60231.94115.74293.51230.10
Summary
Net Change in Cash-231.89133.05-167.17217.27192.10
Cash at Beginning of Period375.25242.21409.37192.100.00
Cash at End of Period143.36374.04242.21409.370.00
Free Cash Flow-182.94-163.40-115.41-76.24-28.06
Supplemental Disclosures
Income Taxes Paid0.470.000.000.000.00